ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

About this update from Immunitybio, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/983bd120e3c92f0cc98b9a8cd1e81b4f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wyLn1y0j8cuUu2YVmhkgUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/983bd120e3c92f0cc98b9a8cd1e81b4f","width":480,"height":270},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dPnOSx2yHQaJypiqz.mpng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/983bd120e3c92f0cc98b9a8cd1e81b4f","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer treatment, with terms extending through at least 2035","length":221,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Claims cover methods of treating non-muscle invasive bladder cancer (NMIBC) including BCG-naïve disease, defined-dose pharmaceutical compositions matching the approved NAI + BCG intravesical regimen, and two-vial commercial kits","length":228,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Portfolio reinforces ImmunityBio's IL-15 receptor agonist plus BCG position as the Company executes its exclusive U.S. Tokyo-172 BCG supply agreement with Japan BCG Laboratory and continues to develop Recombinant BCG (rBCG) to enhance USA supply","length":249,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":698,"olType":false},{"type":"text","content":"CULVER CITY, Calif., May 18, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents have been issued to ImmunityBio covering the combination of its IL-15 receptor agonist ANKTIVA® (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin (BCG) for the treatment of cancer.","length":394,"tagName":"p"},{"type":"text","content":"The five patents (U.S. Patent Nos. 11,173,191; 11,679,144; 11,890,323; 12,268,731; and 12,318,432) with terms extending through at least 2035 include compositions of combina...

More updates from Immunitybio, Inc.